Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.

A user seeks a topical hair loss treatment without minoxidil, considering options like finasteride, dutasteride, caffeine, tretinoin, or prostaglandin analogues. Recommendations include products like Strut, Maximus, Zeuss, and custom formulas from compounding pharmacies.

The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.

Why the top of the head is affected by hair loss more than other areas, and treatments such as surgery, medications like minoxidil, finasteride, and RU58841 to treat it.

Spraying pyrilutamide on the crown area shows noticeable improvement compared to using a dropper. Applying directly to the vertex is challenging without wasting the product.

The user had a hair transplant 10 months ago and sees some improvement but still has thin spots. They previously used finasteride pills and now use a topical solution of minoxidil, dutasteride, and tretinoin.

The user is using topical finasteride, Bioscalin, Omega 3, and hair filler therapy for hair loss. There is some progress noted, but varying photo angles and lighting make it hard to assess fully.

A 24-year-old woman with hair loss due to anemia and possibly thyroid issues is undergoing mesotherapy, which was only applied to the top of her head. She is considering minoxidil and is concerned about the effectiveness of the treatment, as her hair loss is not related to hormonal factors.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.

A user's experimentation with various hair loss treatments, including medications and topical applications; as well as their desire to experience unusual sensations through the use of drugs.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

Human pluripotent stem cells have been used to create hair and skin, potentially offering a new solution for baldness. A user also mentioned starting finasteride but experiencing unexpected hair thinning.

Hair loss treatments Cosmerna, RU, and Pyri discussed. Cosmerna inhibits androgen receptors, but not 100%, so RU/Pyri can be used synergistically.

Topical finasteride in a liposomal formulation reduces systemic absorption compared to ethanol solutions. The user is seeking sources for such products, noting that popular options like morr-f are not liposomal.

Apple core extract pills, believed to enhance hair density, are discussed as a potential treatment for hair loss. Users express cautious optimism and interest in trying the product, while acknowledging skepticism and the high cost.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.

The user is experiencing new hair growth after using oral dutasteride, topical minoxidil, and microneedling, but is concerned about black dots on the hairline, which might be clogged pores or dormant follicles. The user previously used a topical minoxidil/finasteride spray and had good results, despite a shedding phase after switching treatments.

Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

Hair loss may be linked to blood flow and inflammation, with treatments like Minoxidil, finasteride, and quercetin being discussed. The conversation also mentions the role of 5AR enzyme distribution in hair follicles.

The user has been using a topical solution containing minoxidil and finasteride for 10 months but is not satisfied with the results, as there is no significant hair regrowth or thickening. They are questioning whether they are a non-responder or if they should continue the treatment longer.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

Aminexil/Kopexil may help reduce hair loss by addressing perifollicular fibrosis in androgenetic alopecia, but it lacks the extensive clinical backing of finasteride and minoxidil. Some users find it effective, but availability and cost are issues, especially in the US where it's not FDA-approved.